OBJECTIVES: Dulaglutide is a once weekly GLP-1 receptor agonist (RA) indicated for the treatment of type 2 diabetes (T2D). The objective of this retrospective observational study was to assess the change in HbA1c among patients with uncontrolled T2D initiating dulaglutide. METHODS: This analysis included adults with T2D with an initial dulaglutide prescription (index date) between November 2014 and February 2016 using data from the Practice Fusion electronic health record database, which includes >25 million patients (6.7% of US ambulatory care). Patients with ≥1 diagnosis of T2D, naïve to dulaglutide with ≥1 HbA1c result in the 6-month baseline and in the 3 to <6 months post-index period were included. Uncontrolled T2D was defined as baseline HbA1c ≥7%. RESULTS: We identified 734 patients initiating dulaglutide, 187 (25.5%) with baseline HbA1c <7% and 547 (74.5%) with HbA1c ≥7%. At baseline, uncontrolled patients were 48% female, 51% and 49% were prescribed dulaglutide 1.5 mg and 0.75 mg, respectively, with mean±SD age 59.0±10.4 years, BMI 35.9±7.2 kg/m, and HbA1c 8.8±1.5%. During post-index period, the mean reduction in HbA1c was 0.8±1.5%; mean reductions of 0.6±1.5% and 0.9±1.4% were observed among patients with a prior prescription for GLP-1 RA versus those without, respectively (p=.017). Additionally, significant differences in mean HbA1c reduction between subgroups by age (≥65 years vs <65 years: -0.6±1.3% vs -0.8±1.5%; p=.028) and baseline HbA1c (7 to <8% vs 8 to <9% vs ≥9%: -0.1±0.9% vs. -0.6±1.2% vs -1.6±1.8%; p<.001) were observed. There were no significant differences in mean HbA1c reductions between subgroups by gender, race, ethnicity, BMI, previous insulin prescription or oral antidiabetic medications, and dulaglutide dose. CONCLUSIONS: In real-world settings, patients with uncontrolled T2D demonstrated an improvement in their glycemic control within 6 months of initiating dulaglutide.